AbbVie to remain cautious on drug pricing, shares fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
July 31, 2017 9:41 AM EDTMerck (NYSE: MRK) (known as MSD outside the United States and Canada), through a wholly-owned subsidiary today announced that through a collaboration agreement with Generex Biotechnology Corporation and its wholly-owned subsidiary, Antigen Express, Inc has entered into a clinical trial to evaluate Antigens AE37 cancer vaccine in combination with Mercks anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.
The combination of AE37 plus KEYTRUDA follows previous studies, in which both... More
Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
July 31, 2017 9:12 AM EDTAmgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP).The sBLA is based on a Phase 3 study evaluating the safety and efficacy of Prolia... More
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
July 31, 2017 9:03 AM EDTAmgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin® (trastuzumab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA... More
Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
July 28, 2017 4:01 PM EDTAmgen (NASDAQ: AMGN) declared a quarterly dividend of $1.15 per share, or $4.6 annualized.
The dividend will be payable on September 8, 2017, to stockholders of record on August 17, 2017, with an ex-dividend date of August 15, 2017.
The annual yield on the dividend is 2.6 percent.
For a... More
